236
The Lean LaunchPad Lecture 1: Business Models and Customer Development Steve Blank Jon Feiber Ann Miura-Ko John Burke Jerry Engel Jim Hornthal Oren Jacob

Lecture 1 intro bus model cust dev 120411

Embed Size (px)

Citation preview

Page 1: Lecture 1 intro bus model cust dev 120411

The Lean LaunchPad

Lecture 1: Business Models and Customer Development

Steve Blank

Jon Feiber

Ann Miura-Ko

John Burke

Jerry Engel

Jim Hornthal

Oren Jacob

Page 2: Lecture 1 intro bus model cust dev 120411

This Session

• The teaching team• Course objective(s)• Teaching team philosophy• Our expectations of you

Page 3: Lecture 1 intro bus model cust dev 120411

Teaching Team

Page 4: Lecture 1 intro bus model cust dev 120411

Steve Blank, Jon Feiber, John Burke

8 startups in Silicon Valley• Semiconductors• Supercomputers• Consumer electronics• Video games• Enterprise software• Military intelligence

[email protected]@sgblank

www.steveblank.com

• Yale BS EE• McKinsey and Co.• Charles River Ventures• Stanford Ph.D MS&E• TA: E145, Mayfield Fellows,

MS&E 273• V.C. @ Floodgate

[email protected]@annimaniac

• BS CS/Astro Physics U of Colorado

• VP Networking SUN• V.C. @ MDV since 1991

Page 5: Lecture 1 intro bus model cust dev 120411

Steve Blank, Jon Feiber, John Burke

8 startups - 32 years in Silicon Valley• Semiconductors• Supercomputers• Consumer electronics• Video games• Enterprise software• Military intelligence

Teach: Stanford, Berkeley, Columbia

Details at www.steveblank.com

• Yale BS EE• McKinsey and Co.• Charles River Ventures• Stanford Ph.D MS&E• V.C. @ Floodgate

[email protected]@annimaniac

• BS CS/Astro Physics U of Colorado• 50th employee, VP Networking @ Sun• V.C. @ MDV since 1991

[email protected]

Page 6: Lecture 1 intro bus model cust dev 120411

Steve Blank, Jon Feiber, John Burke

8 startups - 32 years in Silicon Valley• Semiconductors• Supercomputers• Consumer electronics• Video games• Enterprise software• Military intelligence

Teach: Stanford, Berkeley, Columbia

Details at www.steveblank.com

• BS Mech Engineering U.C. Berkeley,

• BA Economics U.C. Santa Cruz, • MBA Harvard Business School• Founder BMI Software• VC at ABS Ventures• Co-founder True Ventures

[email protected]@andemca

• BS CS/Astro Physics U of Colorado

• 50th employee, VP Networking @ Su

• V.C. @ MDV since 1991

[email protected]

Page 7: Lecture 1 intro bus model cust dev 120411

Alexander Osterwalder, Tina Seelig

• Ph.D. in Management Information Systems (MIS) University of Lausanne

• Founder, Business Model Foundry• Author Business Model Generation• Co-founder, The Constellation for AIDS

competence (NGO)

Ph.D. Neuroscience Stanford Med School • Mgmt consultant Booz, Allen, Hamilton• Multimedia producer at Compaq Computer • Founder multimedia company BookBrowser.• Exec Director Stanford Technology

Ventures Program (STVP), EpiCenter• [email protected]

• @tseelig

Page 8: Lecture 1 intro bus model cust dev 120411

Oren Jacob, Jim Hornthal

• CEO, stealth startup• EIR, August Capita• lCTO, Pixar• Director, Studio Tools, Pixar• Technical Director, Finding Nemo

• CMEA Capital• Triporati

Page 9: Lecture 1 intro bus model cust dev 120411

Oren Jacob, Jim Hornthal

•CTO Pixar

• CMEA Capital• Chairman Triporati

Page 10: Lecture 1 intro bus model cust dev 120411

Teaching Assistant

• TA’s role: Class/lecture questions, Grading and attendance

Bhavik Joshi

• Better Place (13th employee, first non-Israeli, non-Jewish, non ex-SAP, Asian employee)• Berkeley/Columbia MBA class of 2008/09• Co-founder: Berkeley Stanford Cleantech Conference Series (since 2007)• 2000 – 2007 Enterprise Software • 1998 – 2000 Tata Motors India

[email protected]://about.me/bhavikjoshi

Page 11: Lecture 1 intro bus model cust dev 120411

Alexander Osterwalder, Tina Seelig

8 startups - 32 years in Silicon Valley• Semiconductors• Supercomputers• Consumer electronics• Video games• Enterprise software• Military intelligence

Teach: Stanford, Berkeley, Columbia

Details at www.steveblank.com

• Ph.D. Neuroscience Stanford Med School • Mgmt consultant Booz, Allen, Hamilton• Multimedia producer at Compaq Computer • Founder multimedia company BookBrowser.• Exec Director Stanford Technology Ventures

Program (STVP), EpiCenter [email protected]

@tseelig

Page 12: Lecture 1 intro bus model cust dev 120411

Stephanie Glass

Course Assistant (CA’s)

• MS MS&E 2010

• CA’s role: Class/lecture questions, Grading and attendance

Thomas Haymore

• B.A. in Political Science• Stanford Law (‘06)• J.D. Stanford Law (‘12)

[email protected]

Page 13: Lecture 1 intro bus model cust dev 120411

Stephanie Glass

Course Assistant (CA’s)

• MS MS&E 2012

• CA’s role: Class/lecture questions, Grading and attendance

Thomas Haymore

B.A. in Political Science• Stanford Law (‘06)• J.D. Stanford Law (‘12)

[email protected] [email protected]

Page 14: Lecture 1 intro bus model cust dev 120411

Mentors

• Mentors are people with real-world experience• Mentors role is to:

– Help you “Get you out of the building”– Share contacts– Offer “Real-world” entrepreneurial advice– Critical feedback

• You arrange your schedule for the mentors, not the other way around

Page 15: Lecture 1 intro bus model cust dev 120411

Course Objective: Idea to a Business

• What does it take to go from idea to a business?– Business Model + Customer Development– Hypotheses testing of the business model(s) – Get “out of the building”

Page 16: Lecture 1 intro bus model cust dev 120411

Course Objective: Simulate A Startup?

• Create the pressures, uncertainty, and challenges of a real startup– Our expectations are unreasonable, they require

extraordinary effort– We expect failures, iterations and Pivots– Class is a “lab” - books/lectures are tools, not answers– Fail fast, learn quick, push you outside your comfort zone

Page 17: Lecture 1 intro bus model cust dev 120411

Teaching team philosophy

• This class is taught using the “Startup Culture”– We’re tough, direct, fair - you need to be the same– Startup culture has no hierarchy - in this class you are an

entrepreneur - not a PI, lab mgr or center director– We’re your biggest supporters – we want you to succeed

• Question us, challenge us, push us as hard as we push you

• We don’t pretend to be domain experts, we know you are smarter than we are

Page 18: Lecture 1 intro bus model cust dev 120411

Getting Out of The Building

• This class is not about our lectures• The class is not about your attendance• The class is about the work you do outside the

building• It’s the difference between a vision and a

hallucination

Page 19: Lecture 1 intro bus model cust dev 120411

Our Expectations of You

• This is a full-contact, immersive class– All of you will be full participants – here and remotely– You will spend lots of time outside of your university– You all will do all the work assigned (and it is a lot

more than you probably realize)– No “dine and dash”

• If you think you are not learning, or you all cannot commit the time, see your NSF program manager

Page 20: Lecture 1 intro bus model cust dev 120411

Team Deliverables

• Each Week– Lessons Learned presentation 5 minutes– Updated Lean LaunchLab blog– Hours of “outside the building” learning

• December Presentation– 20 minute Lessons Learned Summary

Page 21: Lecture 1 intro bus model cust dev 120411

What Will you Learn?

• Opportunity evaluation• Search for a Business Model• Customer Discovery and Validation• Operating and decision making in chaos with

insufficient data• Ruthless pursuit of an objective by a team

Page 22: Lecture 1 intro bus model cust dev 120411

The Course ‘By the Numbers’

• 4 Instructors, 1 TA, 15+ Mentors, • 8 Lectures• 8 10-minute presentations per class• 1 Final 20 minute presentation• 2 Textbooks

10-15 hours of work a week outside the classroom

Page 23: Lecture 1 intro bus model cust dev 120411

This Class is Hard

• You can’t pass by attending the lectures• Your grade is determined by the work you do

outside the class• There’s a lot of it• You are dependent on group success –

communication is critical• You don’t need to be friends you need to be

partners

Page 24: Lecture 1 intro bus model cust dev 120411

Class Logistics

Page 25: Lecture 1 intro bus model cust dev 120411

Course Reading

• Business Model Generation• Four Steps to the Epiphany

• www.steveblank.com

Page 26: Lecture 1 intro bus model cust dev 120411

Class Schedule

Eight (3 hour) Class Sessions: • 1: Sept 1st - Introduction, Business Models, Customer Development• 2: Sept 2nd – Value Proposition/Customer Segment• 3: Sept 22nd – Channels• 4: Sept 23rd - Demand Creation (Customer Relationships)• 5: Oct 13th – Revenue Model• 6: Oct 14th – Key Resources and Activities• 7: Nov 11th - Cost Structure • 8: Nov 12th – Fund Raising

9 & 10: Dec 1st / 2nd – Lessons Learned Presentations

Page 27: Lecture 1 intro bus model cust dev 120411

Teams

• team size is 4 people• You chose the roles (hint: no org chart)• Present Weekly and for Final

– Weekly lessons learned– Final is demo and summary

• Class is about discovery and fast iteration

Page 28: Lecture 1 intro bus model cust dev 120411

Team Projects

• Any for-profit scalable startup• If you are a domain expert, that’s your best bet

(but not required)• If you pick a web project, you have to build it

(and there needs to be some novelty)

Page 29: Lecture 1 intro bus model cust dev 120411

Team Deliverables - Presentation

• Each Week– Lessons Learned presentation 10 minutes– Updated business model canvas– Update blog/wiki– 10’s of hours of “outside the building” progress

• Final Presentation– 20 minute Lessons Learned Summary

Page 30: Lecture 1 intro bus model cust dev 120411

Team Deliverables - Blog

• Each Week– Business model canvas updates– Interviews– Photos/Videos– A/B tests– Strategy

Page 31: Lecture 1 intro bus model cust dev 120411

Grading

Individual - 15%• Participation in class 15%

Team - 85%• 40% out-of-the-building

progress as measured by blog write-ups each week.

• 20% weekly team “lesson learned” summaries

• 25% team final report

Grade is on how much you learn

Page 32: Lecture 1 intro bus model cust dev 120411

Grading

Individual - 15%• Participation in class 15%

Team - 80%• 40% out-of-the-building

progress as measured by blog write-ups each week.

• 20% weekly team “lesson learned” summaries

• 25% team final report

You’re graded on how much learn, not how much you sell

Bhavik Joshi
how much you learn
Page 33: Lecture 1 intro bus model cust dev 120411

Office Hours

• With your team• Before and after class• Look at availability here• Get on the calendar

Page 34: Lecture 1 intro bus model cust dev 120411

Intellectual Property - Suggestions

• Make sure your project is OK with your company– disclose to team what IP rights your company has to inventions

• You own what IP you brought to class with you – No team member has claim to anything you brought

• Your team jointly owns any IP developed for the class– If any of you decide to start a company based on the class, you

own only what was developed and completed in the class– You have no claim for work done before or after the class quarter– If a subset of the team decides to start a company they do NOT

“owe” anything to other team members for work done in and during the class

– All team members are free to start the same company, without permission of the others

• You are agreeing to this unless the team decides in writing to do something different

Page 35: Lecture 1 intro bus model cust dev 120411

Class Disclosure/NDA’s

• Successful startups are not about the original idea – It’s about learning, discovery and execution– You will not be presenting your IP/technical details

• You get to see how previous teams solved problems by looking at their slides, notes and blogs

Therefore:

• Your slides, notes and blogs will be public• This is an open class. No non-disclosures

Page 36: Lecture 1 intro bus model cust dev 120411

What’s A Company?

Page 37: Lecture 1 intro bus model cust dev 120411

What’s A Company?

A business organization which sells a product or service in exchange for revenue

and profit

Page 38: Lecture 1 intro bus model cust dev 120411

How Are Companies Organized?

Page 39: Lecture 1 intro bus model cust dev 120411

How Are Companies Organized?

Companies are organized around Business Models

Page 40: Lecture 1 intro bus model cust dev 120411

What’s a Business Model?

Page 41: Lecture 1 intro bus model cust dev 120411

What’s a Business Model?

A business model describes all the parts of the company necessary to make money

Page 42: Lecture 1 intro bus model cust dev 120411

What About My Technology?

Page 43: Lecture 1 intro bus model cust dev 120411

What About My Technology?

Your technology is one of the many critical pieces necessary to build a company.

It is part of the “Value Proposition”

Page 44: Lecture 1 intro bus model cust dev 120411

What About My Technology?

Customers don’t care about your technology

They are trying to solve a problem

Page 45: Lecture 1 intro bus model cust dev 120411

What’s A Startup?

Page 46: Lecture 1 intro bus model cust dev 120411

What’s A Startup?

A startup is a temporary organization designed to search for a repeatable

and scalable business model

Page 47: Lecture 1 intro bus model cust dev 120411

How to Build A Startup

Idea

Business Model

Size Opportunity

Customer Development

Page 48: Lecture 1 intro bus model cust dev 120411

How to Build A Startup

IdeaBusiness Model(s)

Size of the Opportunity

Customer Discovery

Customer Validation

Page 49: Lecture 1 intro bus model cust dev 120411

How to Build A Startup

IdeaSize of the Opportunity

Business Model(s)

Customer Discovery

Customer Validation

Theory Practice

Business Model(s)

Size of the Opportunity

Page 50: Lecture 1 intro bus model cust dev 120411

How to Build A Startup

IdeaSize of the Opportunity

Business Model(s)

Customer Discovery

Customer Validation

• Web startups get the product in front of customers earlier

Business Model(s)

Size of the Opportunity

Page 51: Lecture 1 intro bus model cust dev 120411

How to Build A Startup

IdeaSize of the Opportunity

Business Model(s)

Customer Discovery

Customer Validation

Business Model(s)

Size of the Opportunity

Page 52: Lecture 1 intro bus model cust dev 120411

buzzgroup

Page 53: Lecture 1 intro bus model cust dev 120411
Page 54: Lecture 1 intro bus model cust dev 120411

?A business model describes all the parts of the company necessary to make money

Page 55: Lecture 1 intro bus model cust dev 120411

?what are those parts? what parts is a business model composed of?

Page 56: Lecture 1 intro bus model cust dev 120411

56

Page 57: Lecture 1 intro bus model cust dev 120411

? ?

Page 58: Lecture 1 intro bus model cust dev 120411
Page 59: Lecture 1 intro bus model cust dev 120411
Page 60: Lecture 1 intro bus model cust dev 120411
Page 61: Lecture 1 intro bus model cust dev 120411

Business Model Canvas

Page 62: Lecture 1 intro bus model cust dev 120411

to describe, challenge, design, and invent business models more systematically

Page 63: Lecture 1 intro bus model cust dev 120411

building blocks 9

Page 64: Lecture 1 intro bus model cust dev 120411

CUSTOMER SEGMENTS

images by JAM

Page 65: Lecture 1 intro bus model cust dev 120411

VALUE PROPOSITIONS

images by JAM

Page 66: Lecture 1 intro bus model cust dev 120411

CHANNELS

images by JAM

Page 67: Lecture 1 intro bus model cust dev 120411

CUSTOMER RELATIONSHIPS

images by JAM

Page 68: Lecture 1 intro bus model cust dev 120411

REVENUE STREAMS

images by JAM

Page 69: Lecture 1 intro bus model cust dev 120411

KEY RESOURCES

images by JAM

Page 70: Lecture 1 intro bus model cust dev 120411

KEY ACTIVITIES

images by JAM

Page 71: Lecture 1 intro bus model cust dev 120411

KEY PARTNERS

images by JAM

Page 72: Lecture 1 intro bus model cust dev 120411

COST STRUCTURE

images by JAM

Page 73: Lecture 1 intro bus model cust dev 120411

images by JAM

customer segments

key partners

cost structure

revenue streams

channels

customer relationships

key activities

key resources

value proposition

Page 74: Lecture 1 intro bus model cust dev 120411

images by JAM

customer segments

key partners

cost structure

revenue streams

channels

customer relationships

key activities

key resources

value proposition

Page 75: Lecture 1 intro bus model cust dev 120411

images by JAM

Page 76: Lecture 1 intro bus model cust dev 120411

CANVAS OVERLAY

images by JAM

OFFER

CHANNELS

CUSTOMER RELATIONSHIPS

CUSTOMERSEGMENTS

REVENUE STREAMSCOST STRUCTURE

KEYACTIVITIES

KEYPARTNERS

KEYRESOURCES

Page 77: Lecture 1 intro bus model cust dev 120411

images by JAM

CANVAS OVERLAYOFFER

CHANNELS

CUSTOMER RELATIONSHIPS

CUSTOMERSEGMENTS

REVENUE STREAMSCOST STRUCTURE

KEYACTIVITIES

KEYPARTNERS

KEYRESOURCES

Page 78: Lecture 1 intro bus model cust dev 120411

Business Model Canvas

building block

building block

building block

building block

building block

building block

building block

building block

building block

building block

building blockbuilding

block

building block

building block

Page 79: Lecture 1 intro bus model cust dev 120411

79

illustration

Page 80: Lecture 1 intro bus model cust dev 120411
Page 81: Lecture 1 intro bus model cust dev 120411

?why should some of the smartest scientists in the world waste their time thinking about a business model for coffee?

Page 82: Lecture 1 intro bus model cust dev 120411

!not just because most scientists drink a lot of coffee. we can learn a lot from innovative business models across industries

Page 83: Lecture 1 intro bus model cust dev 120411

how much did the cost of home coffee consumption change for Swiss households over the last couple of years?

Page 84: Lecture 1 intro bus model cust dev 120411

600% to 800% more

Page 85: Lecture 1 intro bus model cust dev 120411
Page 86: Lecture 1 intro bus model cust dev 120411

Nespresso changed the

business (model) for

espresso

Page 87: Lecture 1 intro bus model cust dev 120411

RESULTS

Page 88: Lecture 1 intro bus model cust dev 120411

one of the fastest-growing businesses in the Nestlé group

Page 89: Lecture 1 intro bus model cust dev 120411

average growth of 30% p.a. since 2000

Page 90: Lecture 1 intro bus model cust dev 120411

over 3 billion CHF annual revenue with 1 product line(3.2 bio USD)

Page 91: Lecture 1 intro bus model cust dev 120411

91

buzz group

Page 92: Lecture 1 intro bus model cust dev 120411

?Discuss and describe how you would design a business model around Nespresso’s invention

Page 93: Lecture 1 intro bus model cust dev 120411
Page 94: Lecture 1 intro bus model cust dev 120411

94

?

? ?

?

?

??

?

?

Page 95: Lecture 1 intro bus model cust dev 120411

95

Nespresso machines

retail mailorder

Nespresso

.com

callcenter

Nespresso stores

households

business

1 x machinesales

repetitive pod sales

distribution

channels

coffeeproduction facilites

production

B2C distributi

onbrand

marketing

brandpatents

machine

manufactur

er

production

B2C

distributi

onbrand

marketing

Nespresso club

brandbrand

Nespresso pods

Page 96: Lecture 1 intro bus model cust dev 120411

but Nespresso almost failed in 1987 due to a nonperforming business model

Page 97: Lecture 1 intro bus model cust dev 120411

97

Nespresso system

offices

joint venture with

manufacturer

machine

manufactur

er

Page 98: Lecture 1 intro bus model cust dev 120411
Page 99: Lecture 1 intro bus model cust dev 120411

?what is the most powerful about using a shared language, such as the Business Model Canvas?

Page 100: Lecture 1 intro bus model cust dev 120411
Page 101: Lecture 1 intro bus model cust dev 120411
Page 102: Lecture 1 intro bus model cust dev 120411
Page 103: Lecture 1 intro bus model cust dev 120411

buzz group

Page 104: Lecture 1 intro bus model cust dev 120411
Page 105: Lecture 1 intro bus model cust dev 120411

105

?

? ?

?

?

??

?

?

Page 106: Lecture 1 intro bus model cust dev 120411

possible alternatives

Page 107: Lecture 1 intro bus model cust dev 120411

107

radiation-freedetection of breast cancer

hospitals

Page 108: Lecture 1 intro bus model cust dev 120411

108

proprietary IPmedical device manufacturers

Page 109: Lecture 1 intro bus model cust dev 120411

109

?

? ?

?

?

??

?

?

Page 110: Lecture 1 intro bus model cust dev 120411
Page 111: Lecture 1 intro bus model cust dev 120411

But,Realize They’re Hypotheses

Page 112: Lecture 1 intro bus model cust dev 120411

9 Guesses

Guess Guess

Guess

Guess

GuessGuess

Guess

GuessGuess

Page 113: Lecture 1 intro bus model cust dev 120411

How Does This Really Work?

Stanford Lean LaunchPad Class

8 Weeks From an Idea to a Business

Page 114: Lecture 1 intro bus model cust dev 120411

MammOpticsFinal project presentation for E 245 Winter 2011

Page 115: Lecture 1 intro bus model cust dev 120411

MammOpticsInitial Idea

Breast cancer

Leading cause of cancer in women190,000 diagnosis every year US41,000 deaths every year USIncreasing diagnosis rates

Mammography

15%-25% false negatives rate25% false positives rateRequires X-ray radiationLow resolution

Novel technology based on RF-modulated optical spectroscopy

MammOptics

- Earlier detection- Non-radiative- Non-invasive

Page 116: Lecture 1 intro bus model cust dev 120411

MammOpticsTechnology Comparison

RiskInvasiveness

Resolution

False Pos.

False Neg.

Device Cost

Time Require

d

MammOptics

Mammography

High High .6 cm 25% 30% 20-50k 20 min.

MRI Medium Medium .1 cm 70% 5% 1000k 45 min.

Ultra-Sound Very Low Very Low >.6 cm >30% >40% 5-15k 20 min.

I.I.T.Y.I.W.H.T.K.Y

Page 117: Lecture 1 intro bus model cust dev 120411

MammOpticsBusiness Model Canvas 1 of 4

Radiation-freeEarlier detectionNon-invasive

Pioneering radiologists inhospitals

Direct sales to hospitals

Strong clinical dataTrainingMaintenance

Product DevelopmentClinical trialsOperating Costs Capital equipment

sales and disposable item

Product DevelopmentIPClinical trialsFDA

IP Leading doctorsTechnical Expertise

HospitalsLeading doctors3rd party manufacturersDistributors

Page 118: Lecture 1 intro bus model cust dev 120411

MammOpticsBusiness Model Canvas 1 of 4

Radiation-freeEarlier detectionNon-invasive

Pioneering radiologists inhospitals

Direct sales to hospitals

Strong clinical dataTrainingMaintenance

Product DevelopmentClinical trialsOperating Costs Capital equipment

sales and disposable item

Product DevelopmentIPClinical trialsFDA

IP Leading doctorsTechnical Expertise

HospitalsLeading doctors3rd party manufacturersDistributors

Initi

al guess

Initi

al guess

Initi

al guess

Initi

al guess

MammOpticsBusiness Model Canvas 1 of 4

Test:Customer segment

Value proposition

Page 119: Lecture 1 intro bus model cust dev 120411

Finding the right customerFrom radiologists to gynecologists

Page 120: Lecture 1 intro bus model cust dev 120411

MammOpticsExcursions into hospitals

Leading doctors

Patients

Hospital Managers

Technicians

Debra Ikeda Jason Davies

Jafi Alissa LipsonSunita Pal

6 women >40 8 women <40

Alicia X-ray mammography

Paul BillingsHolly V. Gautier

Page 121: Lecture 1 intro bus model cust dev 120411

MammOpticsHospital purchasing decision tree

Page 122: Lecture 1 intro bus model cust dev 120411

MammOpticsHospital purchasing decision tree

Hospitals

Complex purchasing decision

tree. Several saboteours

Page 123: Lecture 1 intro bus model cust dev 120411

MammOpticsPrivate practice purchasing decision tree

Page 124: Lecture 1 intro bus model cust dev 120411

MammOpticsPrivate practice purchasing decision tree

Private practice

Faster adoption rate

Attractive value proposition✔

Page 125: Lecture 1 intro bus model cust dev 120411

Pioneering DoctorsHospitalsOB/GYNsPCPs

Direct Sales to doctors

Strong clinical dataTrainingMaintenance

Product DevelopmentClinical trialsOperating Costs

Capital Equipment Sales and disposable item

Product DevelopmentIPClinical trialsFDA

IP Leading doctorsTechnical Expertise

Hospitals (Capital Spending Committee)Leading doctors3rd party manufacturersDistributorsResearch Hospitals

Doctors:Earlier detectionPriceAccuracy

Patients:Radiation FreeNon-Invasive

MammOpticsBusiness Model Canvas 2 of 4

Page 126: Lecture 1 intro bus model cust dev 120411

Pioneering DoctorsHospitalsOB/GYNsPCPs

Direct Sales to doctors

Strong clinical dataTrainingMaintenance

Product DevelopmentClinical trialsOperating Costs

Capital Equipment Sales and disposable item

Product DevelopmentIPClinical trialsFDA

IP Leading doctorsTechnical Expertise

Hospitals (Capital Spending Committee)Leading doctors3rd party manufacturersDistributorsResearch Hospitals

Doctors:Earlier detectionPriceAccuracy

Patients:Radiation FreeNon-Invasive

MammOpticsBusiness Model Canvas 2 of 4

How do we get to our customer?

Need sensitivity and specificity

Page 127: Lecture 1 intro bus model cust dev 120411

Getting to our customerThe world of direct sales and medical marketing

Page 128: Lecture 1 intro bus model cust dev 120411

MammOpticsInterviews

Breast Cancer Advocacy Groups

OB/GYNs

FDA/Clinical Trials

Medical Sales

Be Bright PinkJennifer Glover

Dr. Cindy WooDr. Jags Powers

Dr. Aaron Shuvkan

Katrina BellTanay Dudhela

Jed Hwang

Phyllis WhitelyCarl Simpson

Page 129: Lecture 1 intro bus model cust dev 120411

MammOpticsMarketing

Page 130: Lecture 1 intro bus model cust dev 120411

Access to ACOG by former member

Strong influence on doctors via ACOG Standard of Care

Strongly influenced by

KOLs

MammOpticsMarketing

Page 131: Lecture 1 intro bus model cust dev 120411

Researchers conducting

important clinical trials

Researchers with numerous

publications

Outsourced survey research

Researchers with strong peer

recommendations

MammOpticsMarketing

Page 132: Lecture 1 intro bus model cust dev 120411

Focus on prominent journals Need two big

publications

Choose KOL as Principal Investigators (PI)

MammOpticsMarketing

Page 133: Lecture 1 intro bus model cust dev 120411

Effective method for educating doctors

Doctors required to attend workshops

Workshop must be approved by ACOG

Taught by objective medical experts

MammOpticsMarketing

Page 134: Lecture 1 intro bus model cust dev 120411

ACOG Annual Clinical Meeting

Miami Breast Cancer Conference

Opportunity for feedback from

doctors

MammOpticsMarketing

Page 135: Lecture 1 intro bus model cust dev 120411

Trusted information source for patients

Critical opinion leader for technology adoption

Access to media outlets

MammOpticsMarketing

Page 136: Lecture 1 intro bus model cust dev 120411

IndividualDoctors

Purchasing Administrato

rs

High value medical products

(e.g. cardiovascular stents)

Commodity medical products

(e.g. latex gloves)

• Doctor education• Direct feedback from doctors• Very expensive

• No doctor education• No customer feedback• Inexpensive

Direct Sales

Distributors

MammOpticsChannel Strategies and Costs

Individual Doctors

Purchasing Administrato

rs

Page 137: Lecture 1 intro bus model cust dev 120411

Channel Strategies and CostsMammOptics

5 dedicated sales people$150,000 each/year

Hire nurses or technicianswith establishedrelationships

Early adopter feedback

Continue with core group of sales people

Use women’s healthcare equipment distributor

Already established network of customers

Sales strategy 1 Sales strategy 2

Page 138: Lecture 1 intro bus model cust dev 120411

MammOpticsPricing Strategy

Equipment Lease model

Per-use model

Consumable

Cost of the device

Service per year

Per-use fee

Consumable

$50,000

$3,000

0

0

$5,000

$10,000

0

0

$5,000

0

$50

0

$25,000

0

0

$20

Page 139: Lecture 1 intro bus model cust dev 120411

MammOpticsPricing Strategy

Equipment Lease model

Per-use model

Consumable

Cost of the device

Service per year

Per-use fee

Consumable

$50,000

$3,000

0

0

$5,000

$10,000

0

0

$5,000

0

$50

0

$25,000

0

0

$20

Approved by

customers and

investors

Page 140: Lecture 1 intro bus model cust dev 120411

ACOGACS

Doctor specialty

committee

Hospital Administrati

on

Technician

RadiologistMammography

MammOpticsCustomer Workflow

Current market Insurance

Page 141: Lecture 1 intro bus model cust dev 120411

ACOGACS

Doctor specialty

committee

Hospital Administrati

on

Technician

RadiologistMammography

MammOpticsCustomer Workflow

Current market

But what would happen if we replace mammography?

Insurance

Page 142: Lecture 1 intro bus model cust dev 120411

ACOGACS

Doctor specialty

committee

Hospital Administrati

on

Technician

Radiologist

Mammography

MammOpticsCustomer Workflow

Breast Radiologists

Technicians Hospitals

Loss of jobs

Loss of jobs Eliminates loss leaderPuts emphasis on

biopsies

Insurance

Page 143: Lecture 1 intro bus model cust dev 120411

ACOGACS

Doctor specialty

committee

Hospital Administrati

on

Technician

Radiologist

Mammography

MammOpticsCustomer Workflow

Insurance

Page 144: Lecture 1 intro bus model cust dev 120411

ACOGACS

Doctor specialty

committee

Hospital Administrati

on

Technician

Radiologist

Mammography

MammOpticsCustomer Workflow

InsuranceSame cost as mammography

($140)Reduced number of biopsies

($1000)

ACOG/ACSImproved healthcare(mammography weak

technique)

Insurance

Page 145: Lecture 1 intro bus model cust dev 120411

ACOGACS

Doctor specialty

committee

Hospital Administrati

on

Technician

Insurance

Radiologist

Mammography

MammOpticsCustomer Workflow

Page 146: Lecture 1 intro bus model cust dev 120411

Insurance

Doctor specialty

committee

Hospital Administrati

on

Technician

RadiologistMammography

MammOpticsCustomer Workflow

ACOGACS

MammOptics

Patient

PCPOB/GYN

Page 147: Lecture 1 intro bus model cust dev 120411

Insurance

Doctor specialty

committee

Hospital Administrati

on

Technician

Radiologist

Mammography

MammOpticsCustomer Workflow

ACOGACS

MammOptics

Patient

PCPOB/GYN

Hospital Administrati

on

Technician

Radiologist

Mammography

MammOptics

Patient

PCPOB/GYN

PCP OB/GYNsIncreased revenue

More complete patient care

PatientImproved healthcare

Comfort

MammOpticsRevenue

Page 148: Lecture 1 intro bus model cust dev 120411

ACOGACS

Doctor specialty

committee

Hospital Administrati

on

Technician

Insurance

Radiologist

Mammography

MammOpticsCustomer Workflow

MammOptics

Patient

PCPOB/GYN

Page 149: Lecture 1 intro bus model cust dev 120411

OB/GYNsPCPs

Direct Sales to hospitalsDistributor

Strong clinical dataTrainingMaintenanceConferencesCME courses

Product DevelopmentClinical trialsOperating CostsMarketing Costs

Capital Equipment Sales and disposable itemPer use fees

Product DevelopmentIPClinical trialsFDAPublishing

IP Leading doctorsTechnical Expertise

Leading doctorsKey Opinion Leaders3rd party manufacturersDistributorsBreast Cancer FoundationsACOGACS

Doctors:Earlier detectionPriceAccuracy

Patients:Radiation FreeNon-Invasive

MammOpticsBusiness Model Canvas 3 of 4

Page 150: Lecture 1 intro bus model cust dev 120411

OB/GYNsPCPs

Direct Sales to hospitalsDistributor

Strong clinical dataTrainingMaintenanceConferencesCME courses

Product DevelopmentClinical trialsOperating CostsMarketing Costs

Capital Equipment Sales and disposable itemPer use fees

Product DevelopmentIPClinical trialsFDAReimbursementPublishing

IP Leading doctorsTechnical Expertise

Leading doctorsKey Opinion Leaders3rd party manufacturersDistributorsBreast Cancer FoundationsACOGACS

Doctors:Earlier detectionPriceAccuracy

Patients:Radiation FreeNon-Invasive

MammOpticsBusiness Model Canvas 3 of 4

Learned how to reach the customer

How do we build a company based on this?

Page 151: Lecture 1 intro bus model cust dev 120411

Building the companyThe backstage of a medical device company

Page 152: Lecture 1 intro bus model cust dev 120411

MammOpticsInterviews

FDA Clinical Trials

Manufacturing

Venture Capitalists

Reimbursement

Stanford Statistics Steve AxelrodMarga Ortigas-

Wedekind

Nick MourlasDon

Archambault

Shannon BergstedtAli Habib

Dana MeadBill Starling

Doctors/Sales

Dr. Aron Shuftan

Jed HwangMichael J. Nohr

Page 153: Lecture 1 intro bus model cust dev 120411

Manufacturing

MammOpticsPartners

Choose manufacturing facility close to

home

Page 154: Lecture 1 intro bus model cust dev 120411

Manufacturing Reimbursement

MammOpticsPartners

Difficult to get coverage for new product.

Manufacturing

MammOpticsPartners

Page 155: Lecture 1 intro bus model cust dev 120411

Reimbursement PartnersMammOptics

Insurances

CPT Codes$75-$150

Page 156: Lecture 1 intro bus model cust dev 120411

MammOpticsPartners

Manufacturing

FDA Clinical Trials

Reimbursement

510K vs. PMALargest cost

Biggest financial risk

Page 157: Lecture 1 intro bus model cust dev 120411

Clinical Trials

12/4/2009

Stage 1Pilot trials

50 patients$600K

MammOptics

6 months

FeasibilityComparison

with mammograph

y

Page 158: Lecture 1 intro bus model cust dev 120411

Clinical Trials

12/4/2009

MammOptics

6 months 15 months

Stage 1Pilot trials

Stage 2Interim trials

500 patients$7.2M

Prove superior safety-

efficacy & sensitivity

Page 159: Lecture 1 intro bus model cust dev 120411

Clinical Trials

12/4/2009

MammOptics

6 months 15 months

Stage 1Pilot trials

Stage 2Interim trials

24 months

Stage 3FDA

pivotal trials1500

patients$20.5M

FDA class II, 510(K) w/ trials

Focus on superiority &

economic end-points

Page 160: Lecture 1 intro bus model cust dev 120411

Clinical Trials

12/4/2009

MammOptics

6 months 15 months

Stage 1Pilot trials

Stage 2Interim trials

Stage 3FDA

pivotal trials

Stage 4Post-

market studies2000 patients$26.8M

Specific Cat III CPT/ACP CodesMarket traction

24 months24 months

Page 161: Lecture 1 intro bus model cust dev 120411

Clinical Trials

12/4/2009

MammOptics

6 months 15 months

Stage 1Pilot trials

Stage 2Interim trials

Stage 3FDA

pivotal trials$600K

$7.2M

$20.5M

$26.8M

Stage 4Post-

market studies

24 months 24 months

Page 162: Lecture 1 intro bus model cust dev 120411

MammOpticsPartners

MammOpticsPartners

Manufacturing

FDA Clinical Trials

Reimbursement

Financial timeline

Funding

Page 163: Lecture 1 intro bus model cust dev 120411

$10M

$15M

2012

Series A $3.5 MM

Cash

Rese

rve

Clin

ical

Mile

stones

$5M

Initialize

Desi

gn

Mile

stones

Reg

ula

tory

/ IP

M

ilest

ones

Q1 Q2 Q3 Q4

2013Q1 Q2 Q3 Q4

2014Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4

2015 2016

Series B $9 MM

System

2017Q1 Q2Q1 Q2 Q3 Q4

2018Q3

Launch

Series C $30.5 MM

$30M

$20M

Regulatory / Clinical

Series D $35

MM

M&A / IPO $50 MM

$40M

163 12/4/2009

Proof of Concep

t

Pilot Studie

s

IC and Processing Patents

Marketable Product

Provisional Patent

Beta-Versio

n Testin

g

Application and

System Patents

IRB / IDE

Clinical Results

Second Release

Initial Product Launch

Specific Codes (Cat. I CPT / APC)

Non-Specific Codes

1st Release

Test

2nd Release Test

Publication

Post-Market Clinical Studies

Beta Prototype

US Interim Trials

FDA – Class II – 510 (k) with Clinical Trials

Publication

Financial / Operations Timeline

Cat III

CPT

US Pivotal Clinical Trials

Laboratory

Prototype

Technology

Licensing

MammOpticsMammOptics

Financial timeline

Page 164: Lecture 1 intro bus model cust dev 120411

$10M

$15M

2012

Cash

Rese

rve

Clin

ical

Mile

stones

$5M

Initialize

Desi

gn

Mile

stones

Reg

ula

tory

/ IP

M

ilest

ones

Q1 Q2 Q3 Q4

2013Q1 Q2 Q3 Q4

2014Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4

2015 2016 2017Q1 Q2Q1 Q2 Q3 Q4

2018Q3

$30M

$20M

$40M

164 12/4/2009

Proof of Concep

t

Provisional Patent

Financial / Operations Timeline

Technology

Licensing

MammOpticsMammOptics

Page 165: Lecture 1 intro bus model cust dev 120411

$10M

$15M

2012

Series A $3.5 MM

Cash

Rese

rve

Clin

ical

Mile

stones

$5M

Initialize

Desi

gn

Mile

stones

Reg

ula

tory

/ IP

M

ilest

ones

Q1 Q2 Q3 Q4

2013Q1 Q2 Q3 Q4

2014Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4

2015 2016

System

2017Q1 Q2Q1 Q2 Q3 Q4

2018Q3

$30M

$20M

$40M

165 12/4/2009

Proof of Concep

t

Provisional Patent

Beta-Versio

n Testin

g

Laboratory

Prototype

Beta Prototype

Technology

Licensing

Financial / Operations Timeline

Pilot Studie

s

MammOpticsMammOptics

Page 166: Lecture 1 intro bus model cust dev 120411

$10M

$15M

2012

Series A $3.5 MM

Cash

Rese

rve

Clin

ical

Mile

stones

$5M

Desi

gn

Mile

stones

Reg

ula

tory

/ IP

M

ilest

ones

Q1 Q2 Q3 Q4

2013Q1 Q2 Q3 Q4

2014Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4

2015 2016

Series B $9 MM

System

2017Q1 Q2Q1 Q2 Q3 Q4

2018Q3

$30M

$20M

$40M

166 12/4/2009

IC and Processing Patents

Marketable Product

Beta-Versio

n Testin

g

Application and

System Patents

IRB / IDE

Beta Prototype

Financial / Operations Timeline

Pilot Studie

s

Regulatory / Clinical

Laboratory

Prototype

MammOpticsMammOptics

Page 167: Lecture 1 intro bus model cust dev 120411

$10M

$15M

2012

Cash

Rese

rve

Clin

ical

Mile

stones

$5M

Desi

gn

Mile

stones

Reg

ula

tory

/ IP

M

ilest

ones

Q1 Q2 Q3 Q4

2013Q1 Q2 Q3 Q4

2014Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4

2015 2016

Series B $9 MM

System

2017Q1 Q2Q1 Q2 Q3 Q4

2018Q3

Series C $30.5 MM

$30M

$20M

Regulatory / Clinical

$40M

167

IC and Processing Patents

Application and

System Patents

IRB / IDE

Cat III

CPT

Second Release

1st Release

Test

US Interim Trials US Pivotal Clinical Trials

Publication

Financial / Operations Timeline

Pilot Studie

s

MammOpticsMammOptics

Page 168: Lecture 1 intro bus model cust dev 120411

$10M

$15M

2012

Cash

Rese

rve

Clin

ical

Mile

stones

$5M

Desi

gn

Mile

stones

Reg

ula

tory

/ IP

M

ilest

ones

Q1 Q2 Q3 Q4

2013Q1 Q2 Q3 Q4

2014Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4

2015 2016 2017Q1 Q2Q1 Q2 Q3 Q4

2018Q3

Launch

Series C $30.5 MM

$30M

$20M

Regulatory / Clinical

Series D $35

MM

$40M

168 12/4/2009

Clinical Results

Second Release

Initial Product Launch

Non-Specific Codes

2nd Release Test

Publication

US Interim Trials

FDA – Class II – 510 (k) with Clinical Trials

Publication

Financial / Operations Timeline

US Pivotal Clinical Trials

MammOpticsMammOptics

Page 169: Lecture 1 intro bus model cust dev 120411

$10M

$15M

2012

Cash

Rese

rve

Clin

ical

Mile

stones

$5M

Desi

gn

Mile

stones

Reg

ula

tory

/ IP

M

ilest

ones

Q1 Q2 Q3 Q4

2013Q1 Q2 Q3 Q4

2014Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4

2015 2016 2017Q1 Q2Q1 Q2 Q3 Q4

2018Q3

Launch

$30M

$20M

Regulatory / Clinical

Series D $35

MM

M&A / IPO $50 MM

$40M

12/4/2009

Clinical Results

Initial Product Launch

Specific Codes (Cat. I CPT / APC)

Non-Specific Codes

Publication

Post-Market Clinical Studies

FDA – Class II – 510 (k) with Clinical Trials

Financial / Operations TimelineMammOpticsMammOptics

Page 170: Lecture 1 intro bus model cust dev 120411

$10M

$15M

2012

Series A $3.5 MM

Cash

Rese

rve

Clin

ical

Mile

stones

$5M

Initialize

Desi

gn

Mile

stones

Reg

ula

tory

/ IP

M

ilest

ones

Q1 Q2 Q3 Q4

2013Q1 Q2 Q3 Q4

2014Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4

2015 2016

Series B $9 MM

System

2017Q1 Q2Q1 Q2 Q3 Q4

2018Q3

Launch

Series C $30.5 MM

$30M

$20M

Regulatory / Clinical

Series D $35

MM

M&A / IPO $50 MM

$40M

170 12/4/2009

Proof of Concep

t

Pilot Studie

s

IC and Processing Patents

Marketable Product

Provisional Patent

Beta-Versio

n Testin

g

Application and

System Patents

IRB / IDE

Clinical Results

Second Release

Initial Product Launch

Specific Codes (Cat. I CPT / APC)

Non-Specific Codes

1st Release

Test

2nd Release Test

Publication

Post-Market Clinical Studies

Beta Prototype

US Interim Trials

FDA – Class II – 510 (k) with Clinical Trials

Publication

Financial / Operations Timeline

Cat III

CPT

US Pivotal Clinical Trials

Laboratory

Prototype

Technology

Licensing

MammOpticsMammOptics

Page 171: Lecture 1 intro bus model cust dev 120411

Radiation-freeEarlier detectionNon invasive

Pioneering DoctorsHospitals

Direct Sales to hospitals

Strong clinical dataTrainingMaintenance

Product DevelopmentClinical trialsOperating Costs

Capital Equipment Sales and disposable item

Product DevelopmentIPClinical trialsFDA

IP Leading doctorsTechnical Expertise

HospitalsLeading doctors3rd party manufacturersDistributors

MammOpticsBusiness Model Canvas 1

Page 172: Lecture 1 intro bus model cust dev 120411

Radiation-freeEarlier detectionNon invasive

Pioneering DoctorsHospitals

Direct Sales to hospitals

Strong clinical dataTrainingMaintenance

Product DevelopmentClinical trialsOperating Costs

Capital Equipment Sales and disposable item

Product DevelopmentIPClinical trialsFDA

IP Leading doctorsTechnical Expertise

HospitalsLeading doctors3rd party manufacturersDistributorsResearch Hospitals

MammOpticsBusiness Model Canvas 2

Page 173: Lecture 1 intro bus model cust dev 120411

Pioneering DoctorsHospitals

Direct Sales to hospitals

Strong clinical dataTrainingMaintenance

Product DevelopmentClinical trialsOperating Costs

Capital Equipment Sales and disposable item

Product DevelopmentIPClinical trialsFDA

IP Leading doctorsTechnical Expertise

Hospitals (Capital Spending Committee)Leading doctors3rd party manufacturersDistributorsResearch Hospitals

Doctors:Earlier detectionPriceAccuracy

Patients:Radiation FreeNon-Invasive

MammOpticsBusiness Model Canvas 3

Page 174: Lecture 1 intro bus model cust dev 120411

Pioneering DoctorsHospitalsOB/GYNsPCPs

Direct Sales to hospitals

Strong clinical dataTrainingMaintenance

Product DevelopmentClinical trialsOperating Costs

Capital Equipment Sales and disposable item

Product DevelopmentIPClinical trialsFDA

IP Leading doctorsTechnical Expertise

Hospitals (Capital Spending Committee)Leading doctors3rd party manufacturersDistributorsResearch HospitalsBreast Cancer Foundations

Doctors:Earlier detectionPriceAccuracyImmediate Results

Patients:Radiation FreeNon-Invasive

MammOpticsBusiness Model Canvas 4

Page 175: Lecture 1 intro bus model cust dev 120411

OB/GYNsPCPs

Direct Sales to hospitalsDistributor

Strong clinical dataTrainingMaintenanceConferencesCME courses

Product DevelopmentClinical trialsOperating CostsMarketing Costs

Capital Equipment Sales and disposable item

Product DevelopmentIPClinical trialsFDAReimbursementPublishing

IP Leading doctorsTechnical Expertise

Leading doctorsKey Opinion Leaders3rd party manufacturersDistributorsBreast Cancer FoundationsACOGACS

Doctors:Earlier detectionPriceAccuracy

Patients:Radiation FreeNon-Invasive

MammOpticsBusiness Model Canvas 5

Page 176: Lecture 1 intro bus model cust dev 120411

OB/GYNsPCPs

Direct Sales to hospitalsDistributor

Strong clinical dataTrainingMaintenanceConferencesCME courses

Product DevelopmentClinical trialsOperating CostsMarketing Costs

Capital Equipment Sales and disposable itemPer use fees

Product DevelopmentIPClinical trialsFDAReimbursement Publishing

IP Leading doctorsTechnical Expertise

KOLs3rd party manufacturersDistributorsBreast Cancer FoundationsACOGACS

Doctors:Earlier detectionPriceAccuracyImmediate Results

Patients:Radiation FreeNon-Invasive

MammOpticsBusiness Model Canvas 6

Page 177: Lecture 1 intro bus model cust dev 120411

OB/GYNsPCPs

Direct Sales to hospitalsDistributor

Strong clinical dataTrainingMaintenanceConferencesCME courses

Product DevelopmentClinical trialsOperating CostsMarketing Costs

Per use fees

Product DevelopmentIPClinical trialsFDAReimbursement Publishing

IP Leading doctorsTechnical Expertise

KOLs3rd party manufacturersDistributorsBreast Cancer FoundationsACOGACSClinical trial designer

Doctors:Earlier detectionPriceAccuracyImmediate Results

Patients:Radiation FreeNon-Invasive

MammOpticsBusiness Model Canvas 7

Page 178: Lecture 1 intro bus model cust dev 120411

OB/GYNsPCPs

Direct Sales to hospitalsDistributor

Strong clinical dataTrainingMaintenanceConferencesCME courses

Product DevelopmentClinical trialsOperating CostsMarketing Costs

Per use fees

Product DevelopmentIPClinical trialsFDAReimbursement Publishing

IP Leading doctorsTechnical Expertise

KOLs3rd party manufacturers(local)Breast Cancer FoundationsACOGACSClinical trial designer

Doctors:Earlier detectionPriceAccuracyImmediate Results

Patients:Radiation FreeNon-Invasive

MammOpticsBusiness Model Canvas 8

Page 179: Lecture 1 intro bus model cust dev 120411

OB/GYNsPCPs

Direct Sales to hospitalsDistributor

Strong clinical dataTrainingMaintenanceConferencesCME courses

Product DevelopmentClinical trialsOperating CostsMarketing Costs

Per use fees

Product DevelopmentIPClinical trialsFDAReimbursement Publishing

IP Leading doctorsTechnical Expertise

KOLs3rd party manufacturers(local)Breast Cancer FoundationsACOGACSClinical trial designer

Doctors:Earlier detectionPriceAccuracyImmediate Results

Patients:Radiation FreeNon-Invasive

MammOpticsBusiness Model Canvas 9

Page 180: Lecture 1 intro bus model cust dev 120411

Customer Development

Get Out of the Building and Search for the Business Model

The founders

^

Page 181: Lecture 1 intro bus model cust dev 120411

The Customer Development Process

Customer Discovery

Customer Validation

Customer Creation

Company Building

Pivot

Page 182: Lecture 1 intro bus model cust dev 120411

The Minimum Viable Product (MVP)

• Smallest feature set that gets you the most …

- orders, learning, feedback, failure…

Customer Discovery

Customer Validation

Customer Creation

Company Building

Pivot

Page 183: Lecture 1 intro bus model cust dev 120411

A Pivot is the change of one or more Business Model Canvas Components

Page 184: Lecture 1 intro bus model cust dev 120411

The Pivot

• The heart of Customer Development

• Iteration without crisis

• Fast, agile and opportunistic

Customer Discovery

Customer Validation

Customer Creation

Company Building

Pivot

Page 185: Lecture 1 intro bus model cust dev 120411

Pivot Cycle Time Matters

• Speed of cycle minimizes cash needs

• Minimum feature set speeds up cycle time

• Near instantaneous customer feedback drives feature set

Customer Discovery

Customer Validation

Customer Creation

Company Building

Pivot

Page 186: Lecture 1 intro bus model cust dev 120411

186Source: http://giffconstable.com/

Page 187: Lecture 1 intro bus model cust dev 120411

The Customer Development ProcessCustomer Discovery

Customer Discovery

Customer Validation

Customer Creation

Company Building

Bus Model Canvas

Extract Hypotheses

Test Problem

Test Solution

Pivot or Proceed

Page 188: Lecture 1 intro bus model cust dev 120411

The Customer Development ProcessCustomer Validation

Customer Discovery

Customer Validation

Customer Creation

Company Building

Get Ready to Sell

Sell, Sell, Sell

PositioningPivot or Proceed

Page 189: Lecture 1 intro bus model cust dev 120411

Blog Your Progress

Page 190: Lecture 1 intro bus model cust dev 120411

How?

• Customer Development– The Process

• Narrative– Interviews– Surveys– Videos– Prototypes

• Business Model Canvas– Scorekeeping

• Real-time Feedback• Physical Reality Checks

– Skype– Face-to-face

Page 191: Lecture 1 intro bus model cust dev 120411

We Made Students Blog Their Progress

It Changed Everything

Page 192: Lecture 1 intro bus model cust dev 120411

Interview

Page 193: Lecture 1 intro bus model cust dev 120411

Photos Videos

Page 194: Lecture 1 intro bus model cust dev 120411

Surveys

Page 195: Lecture 1 intro bus model cust dev 120411

Interview& Photos

Page 196: Lecture 1 intro bus model cust dev 120411

Competitive Analysis

Page 197: Lecture 1 intro bus model cust dev 120411

Key Findings

Page 198: Lecture 1 intro bus model cust dev 120411

A/B Test Results

Page 199: Lecture 1 intro bus model cust dev 120411

Key Question

Page 200: Lecture 1 intro bus model cust dev 120411

Strategy

Page 201: Lecture 1 intro bus model cust dev 120411

Business Model Canvas as the Scorecard

Page 202: Lecture 1 intro bus model cust dev 120411

Market Type

Four Types of Markets

Page 203: Lecture 1 intro bus model cust dev 120411

Type of MarketChanges Everything

• Market– Market Size– Cost of Entry– Launch Type– Competitive

Barriers– Positioning

• Sales– Sales Model– Margins– Sales Cycle– Chasm Width

Clone Market

Existing Market Resegmented Market

New Market

• Finance• Ongoing Capital• Time to Profitability

• Customers• Needs• Adoption

Page 204: Lecture 1 intro bus model cust dev 120411

Definitions: Four Types of Markets

• Clone Market– Copy of a U.S. business model

• Existing Market– Faster/Better = High end

• Resegmented Market– Niche = marketing/branding driven– Cheaper = low end

• New Market– Cheaper/good enough, creates a new class of product/customer– Innovative/never existed before

Clone Market

Existing Market Resegmented Market

New Market

Page 205: Lecture 1 intro bus model cust dev 120411

Size of Opportunity

Page 206: Lecture 1 intro bus model cust dev 120411

Market/Opportunity Analysis

How Big is It?: Market/Opportunity Analysis– Identify a Customer and Market Need– Size the Market– Competitors– Growth Potential

Page 207: Lecture 1 intro bus model cust dev 120411

How Big is the Pie?Total Available Market

Total Available Market

• How many people would want/need

the product?

• How large is the market be (in $’s) if they all bought?

• How many units would that be?

How Do I Find Out?

• Industry Analysts – Gartner, Forrester

• Wall Street Analysts – Goldman, Morgan

Page 208: Lecture 1 intro bus model cust dev 120411

How Big is My Slice?Served Available Market

• How many people need/can use product?

• How many people have the money to buy the product

• How large would the market be (in $’s) if they all bought?

• How many units would that be?

How Do I Find Out?• Talk to potential customers

Served Available

Market

TotalAvailableMarket

Page 209: Lecture 1 intro bus model cust dev 120411

How Much Can I Eat?Target Market

• Who am I going to sell to in year 1, 2 & 3?

• How many customers is that?

• How large is the market be (in $’s) if they all bought?

• How many units would that be?

How Do I Find Out?• Talk to potential customers

• Identify and talk to channel partners

• Identify and talk to competitors

TotalAvailableMarket Target

Market

ServedAvailableMarket

Page 210: Lecture 1 intro bus model cust dev 120411

Market Size: Summary

• Market Size Questions:– How big can this market be? – How much of it can we get?– Market growth rate– Market structure (Mature or in flux?)

• Most important: Talk to Customers and Sales Channel• Next important: Market size by competitive approximation

– Wall Street analyst reports are great• And : Market research firms Like Forester, Gartner

Page 211: Lecture 1 intro bus model cust dev 120411

Team Deliverable by Tomorrow

1. Hypotheses for each part of business model2. Test for each of the hypotheses

What  constitutes a pass/fail signal for the test (e.g. at what point would you say your hypotheses wasn’t even close to  correct?

3. Plan to get out of the building to test the hypotheses

• Summarized in a 5 Minute PowerPoint Presentation– Business Model Canvas– Market Size– Getting out of the building plan

Don’t Over Think Your Hypotheses

Page 212: Lecture 1 intro bus model cust dev 120411

Sweet Sensors

Yu Xiang and Yi Lu, Nature Chem. 3, 697-703 (2011).

Glucose Monitor:

• Widely available• Cheap• Quantitative

information• $10 billion market

However, it can detect only one target: glucoseand at very high concentrations

We have developed a novel technology to use any glucose monitor without modifications to detect a wide range of non-glucose targets at very low concentrations(such as diseases (e.g., TB), heavy metal ions (e.g., Pb, Hg), organic toxins, bacteria, viruses and cancers)

Page 213: Lecture 1 intro bus model cust dev 120411

Examples

Page 214: Lecture 1 intro bus model cust dev 120411

Market size

- 300 million patients worldwide

- Required HbA1C testing every 60-90 days

- Available in-home HbA1C tests today are $100/10 tests

- Assuming $1 per test, TAM = $1.2 billion

- Assuming 50% people have the access to a HbA1c test, SAM = $600 million

- Assuming we can capture 20% of SAM (high-end diabetics and early adopters), Target market = $120 million

Total available market = $1.2 billion

Serviceable Available Market = $600 million

Target market = $120 million

Page 215: Lecture 1 intro bus model cust dev 120411

Market Size

• Growing market– Aging population– Living Style & Diets– Chronic disease

• Driving factors– Healthcare costs– Reimbursement– Healthcare labor shortage

Total Available market 170M (US & EU5)

$25B

Target market 3.5M (Resistant Hypertension)$500M

Page 216: Lecture 1 intro bus model cust dev 120411

Diabetics

Sweet SensorsYi Lu, Tian LanNeil KaneChris Sorensen

Business Model Canvas

Clinicians (in rural area)

Triage nurses

Pre-diabetics

Product supports

Patient network/community

Retailers (Walgreen)

Online vendors (Amazon)

Direct sales

Disposable test kit (used repeatedly on a regular basis)

At home

Convenient

Less exposure to infectious diseases in the hospital

Cheaper

More frequent

Better indicator of health (diabetic management)

Conferences

Product R&D

QC

Marketing

IP

Personnel

Glucose monitor manufacturers

Kit manufacturers

Reagent suppliers

Reagents

Manufacture

Licensing

FDA certification?

Page 217: Lecture 1 intro bus model cust dev 120411

Diabetics

Sweet SensorsYi Lu, Tian LanNeil KaneChris Sorensen

Action Plan

Clinicians (in rural area)

Triage nurses

Pre-diabetics

Product supports

Patient network/community

Retailers (Walgreen)

Online vendors (Amazon)

Direct sales

Disposable test kit (used repeatedly on a regular basis)

At home

Convenient

Less exposure to infectious diseases in the hospital

Cheaper

More frequent

Better indicator of health (diabetic management)

Conferences

Product R&D

QC

Marketing

IP

Personnel

Glucose monitor manufacturers

Kit manufacturers

Reagent suppliers

Reagents

Manufacture

Licensing

FDA certification?

Page 218: Lecture 1 intro bus model cust dev 120411

General methodology for adding fluorine to

lead compounds of interest

The Business Model Canvas

Accessibility (RCY)PuritySpeedPET/SPECTMultiplatformSensitivity (nca)Specific compounds

IPPoP dataRegulatory planUnderstanding of the regulatory process

Contract cGMP precursor manufactureSalary, RentsClinical trials

SOPs for precursors and drugsRecruit clinical sitesIn vivo animal studiesDevelop regulatory plan for pre IND meetingID cGMP CROFund-raising

cGMP manufacturerRadiopharmaciesNuclear Medicine and Radiology departments

Technical Assistance (Image Atlas)FDA regulatory support

Radiopharmacies

Equipment producers

Prescribing physicians

Radiologist who perform studies

Sales of intermediates

Technology license

Product license (royalty)

Direct sales of precursor

R&D and clinical studies presented in journals and meetings

Drug developers

Pharmaceutical development companies

IPPoP data

Radiologists

Technical assistance

Page 219: Lecture 1 intro bus model cust dev 120411

General methodology for adding fluorine to

lead compounds of interest

The Business Model Canvas

Accessibility (RCY)PuritySpeedPET/SPECTMultiplatformSensitivity (nca)Specific compounds

IPPoP dataRegulatory planUnderstanding of the regulatory process

Contract cGMP precursor manufactureSalary, RentsClinical trials

SOPs for precursors and drugsRecruit clinical sitesIn vivo animal studiesDevelop regulatory plan for pre IND meetingID cGMP CROFund-raising

cGMP manufacturerRadiopharmaciesNuclear Medicine and Radiology departments

Technical Assistance (Image Atlas)FDA regulatory support

Radiopharmacies

Equipment producers

Prescribing physicians

Radiologist who perform studies

Sales of intermediates

Technology license

Product license (royalty)

Drug developers

Pharmaceutical development companies

IPPoP data

Radiologists

Technical assistance

Direct sales of precursor

R&D and clinical studies presented in journals and meetings

Sales of precursor through global finished pharmaceutical distributor

Page 220: Lecture 1 intro bus model cust dev 120411

Critical Success Factors

• Validation of the need– By talking to diabetic patients, clinician and nurses

• Validation of the customer segmentation– By talking to glucose monitor and kit manufactures

• Evidence of market accessibility– By talking to glucose monitor and kit distributors

Page 221: Lecture 1 intro bus model cust dev 120411

Backup

Page 222: Lecture 1 intro bus model cust dev 120411

Customer Discovery

Bus Model Canvas

Extract Hypotheses

Test Problem

Test Solution

Pivot or Proceed

Page 223: Lecture 1 intro bus model cust dev 120411

Customer Discovery - Physical

Bus Model Canvas

Extract Hypotheses

Test Problem

Test Solution

Pivot or Proceed

• TAM/SAM• Product MVP• Customers• Channel • Market Type• Customer Relationships: Get/Keep/Grow• Key Resources• Partners• Pricing

Page 224: Lecture 1 intro bus model cust dev 120411

Customer Discovery - Web

Bus Model Canvas

Extract Hypotheses

Test Problem

Test Solution

Pivot or Proceed

• TAM/SAM• Low Fidelity MVP• Customers/Source• Channel • Market Type• Customer Relationships: Acquire/Activate• Traffic Partners• Pricing

Page 225: Lecture 1 intro bus model cust dev 120411

Customer Discovery - Physical

Bus Model Canvas

Extract Hypotheses

Test Problem

Test Solution

Pivot or Proceed

• TAM/SAM• Low Fidelity MVP• Customers• Channel • Market Type• Cust Relationships• Traffic Partners• Pricing

• Customer Contacts• Problem Understanding• Customer Understanding• Market Knowledge

Page 226: Lecture 1 intro bus model cust dev 120411

Customer Discovery - Web

Bus Model Canvas

Extract Hypotheses

Test Problem

Test Solution

Pivot or Proceed

• TAM/SAM• Low Fidelity MVP• Customers• Channel • Market Type• Cust Relationships• Traffic Partners• Pricing

• Customer Engagement• Test Low Fidelity MVP• Customer Understanding• Traffic & Competitive Analysis

Page 227: Lecture 1 intro bus model cust dev 120411

Customer Discovery - Physical

Bus Model Canvas

Extract Hypotheses

Test Problem

Test Solution

Pivot or Proceed

• TAM/SAM• Low Fidelity MVP• Customers• Channel • Market Type• Cust Relationships• Traffic Partners• Pricing

• Update Bus Model• Create Prototype/Prod Presentation• Test Solution with Customer• Update Business Model• 1st Advisory Board Members

Page 228: Lecture 1 intro bus model cust dev 120411

Customer Discovery - Web

Bus Model Canvas

Extract Hypotheses

Test Problem

Test Solution

Pivot or Proceed

• TAM/SAM• Low Fidelity MVP• Customers• Channel • Market Type• Cust Relationships• Traffic Partners• Pricing

• Customer Engagement• Test Low Fidelity MVP• Customer Understanding• Traffic & Competitive Analysis

• Update Bus Model• Test High Fidelity MVP• Measure Customer Behavior• Update Business Model• 1st Advisory Board Members

Page 229: Lecture 1 intro bus model cust dev 120411

Customer Discovery – Web/Physical

Bus Model Canvas

Extract Hypotheses

Test Problem

Test Solution

Pivot or Proceed

Verify the:• Value Prop• Cust Segment• Cust Relationships• Channel• Revenue Model• Pivot or Proceed

• TAM/SAM• Low Fidelity MVP• Customers• Channel • Market Type• Cust Relationships• Traffic Partners• Pricing

• Customer Engagement• Test Low Fidelity MVP• Customer Understanding• Traffic & Competitive Analysis

Page 230: Lecture 1 intro bus model cust dev 120411

Customer Validation - Web

Get Ready to Sell

Sell, Sell, Sell

PositioningPivot or Proceed

Pivot

Page 231: Lecture 1 intro bus model cust dev 120411

Customer Validation - Physical

Get Ready to Sell

Sell, Sell, Sell

PositioningPivot or Proceed

• Craft Positioning• Develop Sales Materials• Hire “Sales Closer”• Sales Channel Action Plan• Refine the Sales Roadmap• Formalize advisory board

Page 232: Lecture 1 intro bus model cust dev 120411

Customer Validation - Web

Get Ready to Sell

Sell, Sell, Sell

PositioningPivot or Proceed

• Craft Positioning• Acquire/Activate Plans and Tools• Build High Fidelity MVP• Build Metrics Toolset• Hire data analytics chief • Formalize advisory board

Page 233: Lecture 1 intro bus model cust dev 120411

Customer Validation - Physical

Get Ready to Sell

Sell, Sell, Sell

PositioningPivot or Proceed

• Craft Positioning

• Acquire/Activate Plans• Build High Fidelity MVP• Build Metrics Toolset• Hire data analytics chief • Formalize advisory board

• Find Earlyvangelists• Test Sell – Out of the Building• Refine Sales Roadmap• Test Sell Channel Partners

Page 234: Lecture 1 intro bus model cust dev 120411

Customer Validation - Web

Get Ready to Sell

Sell, Sell, Sell

PositioningPivot or Proceed

• Craft Positioning

• Acquire/Activate Plans• Build High Fidelity MVP• Build Metrics Toolset• Hire data analytics chief • Formalize advisory board

• Prepare Optimization Plans & Tools• Out of the building Activation Test• Measure and Optimize Results• Test Sell Traffic Partners

Page 235: Lecture 1 intro bus model cust dev 120411

Customer Validation - Physical/Web

Get Ready to Sell

Sell, Sell, Sell

PositioningPivot or Proceed

• Craft Positioning• Acquire/Activate Plans• Build High Fidelity MVP• Build Metrics Toolset• Hire data analytics chief • Formalize advisory board

• Prepare Optimization Plans• Out of the building Activation Test• Measure and Optimize Results• Test Sell Traffic Partners

• Company Positioning• Product Positioning• Validate Positioning

Page 236: Lecture 1 intro bus model cust dev 120411

Customer Validation - Physical/Web

Get Ready to Sell

Sell, Sell, Sell

PositioningPivot or Proceed

• Craft Positioning• Acquire/Activate Plans• Build High Fidelity MVP• Build Metrics Toolset• Hire data analytics chief • Formalize advisory board

• Prepare Optimization Plans• Out of the building Activation Test• Measure and Optimize Results• Test Sell Traffic Partners

• Assemble Data• Validate Business Model• Validate Financial Model• Pivot or Proceed